Browse by author
Lookup NU author(s): Professor Andrew Pearson,
Dr Jennifer Kernahan,
Dr Helen Lucraft,
Emeritus Professor Alan Craft
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Ten patients (age range 3.2-26.3 yrs) with relapsed or resistant malignancies received a total of 20 courses of low dose continuous infusion doxorubicin (3 mg/m2/day for 28 days) delivered by portable Graseby infusion pumps via central venous catheters. Each patient received a median dose of 144 mg/m2 (range 87-261). Four patients responded to treatment (1 complete response (CR) and 3 partial response (PR)) and performance status improved in seven patients. Overall toxicity was minimal: WHO Grade 4 anaemia in 2/18 courses, Grade 4 neutropenia in 1/18, Grade 3-4 thrombocytopenia in 3/18, nausea and vomiting of Grades 2 and 4 in 4/20 and 1/20 respectively, and mucositis of Grades 2 and 4 in 2/20 courses each. Cardiac toxicity was assessed using echocardiography, and fractional shortening remained within normal limits in all patients. Low dose continuous infusion doxorubicin is a feasible, well tolerated, ambulatory therapy in children and may be an effective way of delivering doxorubicin with less toxicity, thus enabling the development of more dose intensive regimens. (C) 1993 Wiley-Liss, Inc.
Author(s): Kynaston, J. A., Pearson, A. D. J., Kernahan, J., Lucraft, H. H., Barstow, D., Thompson, A., Craft, A. W.
Publication type: Article
Publication status: Published
Journal: Medical and Pediatric Oncology
ISSN (print): 0098-1532
ISSN (electronic): 1545-5017
PubMed id: 8341217
Altmetrics provided by Altmetric